.png){kind=icon}
返回
E
Erika Hamilton
Sarah Cannon Research Institute
58H指数
842论文数
1.6W被引数
收录论文 214
发表时间
.png){kind=icon}
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 studyDatopotamab deruxtecan与化疗在先前治疗的不可手术/转移性激素受体阳性HER2阴性乳腺癌中的比较：TROPION-Breast01 III期研究的安全性和患者报告结局.png)
ESMO Open.png)
OAAI
ESMO OpenIF8.3
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancerINAVO120随机对照III期试验的安全性分析：评估伊奈利他或安慰剂联合帕博西尼–氟维司群在PIK3CA突变、激素受体阳性、HER2阴性、内分泌耐药的晚期乳腺癌患者中的应用ESMO OpenOAAI
ESMO OpenIF8.3
OAAI分享收藏A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO在一项关于 niraparib 联合 bevacizumab 维持治疗的研究中，该研究在晚期卵巢癌患者接受以 bevacizumab 辅助的一线铂类化疗后进行，报告了 OVARIO 研究的最终分析结果及总生存数据。gynecologic oncology
OAAI
gynecologic oncologyIF4.1
OAAI分享收藏Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a studyZanidatamab联合palbociclib和fulvestrant治疗既往接受过治疗的激素受体阳性、HER2阳性转移性乳腺癌：一项两阶段、多中心、单臂、2a期研究的主要结果
PREAI
分享收藏